Compound Detail
CHEMBL1086440
TRICLABENDAZOLE 💊 Approved Drug
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
💊 Approved Drug
Basic Information
| ChEMBL ID | CHEMBL1086440 |
| Name | TRICLABENDAZOLE |
| Phase | Approved |
| Structure Type | MOL |
| InChI Key | NQPDXQQQCQDHHW-UHFFFAOYSA-N |
| Therapeutic | ✓ Yes |
6
Targets
9
Activities
2
Assay Types
1
PK Parameters
20
Publications
8
Known Names
2
Indications
1
Mechanisms
Molecular Properties
359.7
MW (Da)
6.04
ALogP
3
HBA
1
HBD
37.9
PSA (Ų)
0.58
QED
1
Ro5 Violations
3
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| First Approval | 2019 |
| Availability | Prescription |
| Chirality | Achiral |
Mechanism of Action
| Mechanism | Action Type | Target | Direct | Efficacy |
|---|---|---|---|---|
| Unknown | - | - | ✓ | ✓ |
Indications
Fascioliasis Helminthiasis
ATC Classification
P02BX04
triclabendazole
Level 1: ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS
Level 2: ANTHELMINTICS
Activity Summary
EC50 5 meas. best 5.64
IC50 4 meas. best 5.46
Target Activity Profile
| Target | Type | Best pChEMBL | Mean pChEMBL | Best (nM) | # Data |
|---|---|---|---|---|---|
| Streptococcus sp. 'group A' CHEMBL612389 | EC50 | 5.64 | 5.64 | 2263.0 | 1 |
| Streptokinase A CHEMBL1293228 | EC50 | 5.53 | 5.43 | 2925.0 | 2 |
| Transthyretin CHEMBL3194 | IC50 | 5.46 | 5.46 | 3500.0 | 1 |
| Streptococcus CHEMBL612313 | EC50 | 5.21 | 5.21 | 6223.0 | 1 |
| Cruzipain CHEMBL3563 | IC50 | 4.82 | 4.82 | 15000.0 | 1 |
| Unchecked CHEMBL612545 | IC50 | 4.43 | 4.335 | 37270.0 | 2 |
| Unchecked CHEMBL612545 | EC50 | 4.36 | 4.36 | 43880.0 | 1 |
Pharmacokinetic Data
| Parameter | Value | Units | Species |
|---|---|---|---|
| Tmax | 2.0 | hr | Homo sapiens |
Activity Data Samples
Top measurements by pChEMBL value
Literature References
Data from ChEMBL 36 via Core Engine